

## Azithromycin for COVID-19

# **Azithromycin in Hospitalised Patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial**

**Running title:** Azithromycin for COVID-19

**RECOVERY Collaborative Group\***

\*The writing committee and trial steering committee are listed at the end of this manuscript and a complete list of collaborators in the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial is provided in the Supplementary Appendix.

Correspondence to: Professor Peter W Horby and Professor Martin J Landray, RECOVERY Central Coordinating Office, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF, United Kingdom.

Email: [recoverytrial@ndph.ox.ac.uk](mailto:recoverytrial@ndph.ox.ac.uk)

## Azithromycin for COVID-19

### 23 SUMMARY

24 **Background:** Azithromycin has been proposed as a treatment for COVID-19 on the  
25 basis of its immunomodulatory actions. We evaluated the efficacy and safety of  
26 azithromycin in hospitalised patients with COVID-19.

27 **Methods:** In this randomised, controlled, open-label, adaptive platform trial, several  
28 possible treatments were compared with usual care in patients hospitalised with  
29 COVID-19 in the UK. Eligible and consenting patients were randomly allocated to either  
30 usual standard of care alone or usual standard of care plus azithromycin 500 mg once  
31 daily by mouth or intravenously for 10 days or until discharge (or one of the other  
32 treatment arms). Patients were twice as likely to be randomised to usual care as to any  
33 of the active treatment groups. The primary outcome was 28-day mortality. The trial is  
34 registered with ISRCTN (50189673) and clinicaltrials.gov (NCT04381936).

35 **Findings:** Between 7 April and 27 November 2020, 2582 patients were randomly  
36 allocated to receive azithromycin and 5182 patients to receive usual care alone. Overall,  
37 496 (19%) patients allocated to azithromycin and 997 (19%) patients allocated to usual  
38 care died within 28 days (rate ratio 1.00; 95% confidence interval [CI] 0.90-1.12;  
39  $p=0.99$ ). Consistent results were seen in all pre-specified subgroups of patients. There  
40 was no difference in duration of hospitalisation (median 12 days vs. 13 days) or the  
41 proportion of patients discharged from hospital alive within 28 days (60% vs. 59%; rate  
42 ratio 1.03; 95% CI 0.97-1.10;  $p=0.29$ ). Among those not on invasive mechanical  
43 ventilation at baseline, there was no difference in the proportion meeting the composite

## Azithromycin for COVID-19

44 endpoint of invasive mechanical ventilation or death (21% vs. 22%; risk ratio 0.97; 95%  
45 CI 0.89-1.07; p=0.54).

46 **Interpretation:** In patients hospitalised with COVID-19, azithromycin did not provide  
47 any clinical benefit. Azithromycin use in patients hospitalised with COVID-19 should be  
48 restricted to patients where there is a clear antimicrobial indication.

49 **Funding:** UK Research and Innovation (Medical Research Council) and National  
50 Institute of Health Research (Grant ref: MC\_PC\_19056).

51 **Keywords:** COVID-19, azithromycin, clinical trial.

52

53 **NOTE:**

54 Enrolment to the azithromycin arm of the RECOVERY trial was closed on 27 November  
55 2020. Here we report the preliminary findings based on a data cut on 30 November  
56 2020. Final results will be made available after the last patient has completed the 28-  
57 day follow-up period for the primary outcome on 25 December 2020. As with previous  
58 reports, we anticipate >99% follow-up of all patients due to the linkage with routine NHS  
59 data. With 1483 deaths among a total of 7764 patients included in the current report, the  
60 findings are unlikely to change in any material way.

61

## Azithromycin for COVID-19

### 62 INTRODUCTION

63 A substantial proportion of individuals infected with severe acute respiratory syndrome  
64 coronavirus 2 (SARS-CoV-2) develop a respiratory illness requiring hospital care, which  
65 can progress to critical illness with hypoxic respiratory failure requiring prolonged  
66 ventilatory support. Among COVID-19 patients admitted to UK hospitals in the first wave  
67 of the epidemic, the case fatality rate was over 26%, and in excess of 37% in patients  
68 requiring invasive mechanical ventilation.<sup>1</sup>

69 Among patients with severe COVID-19, the host immune response is thought to play a  
70 key role in driving an acute pneumonic process with diffuse alveolar damage,  
71 inflammatory infiltrates, and microvascular thrombosis.<sup>2</sup> The beneficial effects of  
72 dexamethasone and other corticosteroids in patients with hypoxic lung damage suggest  
73 that other drugs that suppress or modulate the immune system may provide additional  
74 improvements in clinical outcomes.<sup>3,4</sup>

75 Macrolide antibiotics, such as azithromycin, clarithromycin and erythromycin, are widely  
76 available and their safety is well established. In addition to antibacterial properties, they  
77 are known to have immunomodulatory activity, decreasing production of pro-  
78 inflammatory cytokines and inhibiting neutrophil activation.<sup>5-7</sup> They are widely used both  
79 in bacterial pneumonia due to their antimicrobial activity and in chronic inflammatory  
80 lung disease due to their immunomodulatory effects.<sup>8,9</sup> In addition, azithromycin has *in*  
81 *vitro* antiviral activity against a range of viruses including SARS-CoV-2.<sup>10,11</sup>

82 The use of macrolides in influenza-associated pneumonia has been associated with a  
83 faster reduction in inflammatory cytokines and, in combination with naproxen,

## Azithromycin for COVID-19

decreased mortality.<sup>12-14</sup> However, randomised trials have so far failed to demonstrate convincing clinical benefit of macrolides in COVID-19.<sup>15-17</sup> Here we report the preliminary results of a randomised controlled trial of azithromycin in patients hospitalised with COVID-19.

## METHODS

### Study design and participants

The Randomised Evaluation of COVID-19 therapy (RECOVERY) trial is an investigator-initiated, individually randomised, controlled, open-label, adaptive platform trial to evaluate the effects of potential treatments in patients hospitalised with COVID-19. Details of the trial design and results for other possible treatments (dexamethasone, hydroxychloroquine, and lopinavir-ritonavir) have been published previously.<sup>3,18,19</sup> The trial is underway at 176 hospitals in the United Kingdom (appendix pp 2-22), supported by the National Institute for Health Research Clinical Research Network. The trial is coordinated by the Nuffield Department of Population Health at the University of Oxford (Oxford, UK), the trial sponsor. The trial is conducted in accordance with the principles of the International Conference on Harmonisation–Good Clinical Practice guidelines and approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the Cambridge East Research Ethics Committee (ref: 20/EE/0101). The protocol, statistical analysis plan, and additional information are available on the study website [www.recoverytrial.net](http://www.recoverytrial.net).

## Azithromycin for COVID-19

105 Although the azithromycin, dexamethasone, hydroxychloroquine, and lopinavir-ritonavir  
106 arms have now been stopped, the trial continues to study the effects of tocilizumab,  
107 convalescent plasma, REGEN-COV2 (a combination of two monoclonal antibodies  
108 directed against SARS-CoV-2 spike glycoprotein), aspirin, and colchicine. Other  
109 treatments may be studied in future.

110 Patients admitted to hospital were eligible for the study if they had clinically suspected  
111 or laboratory confirmed SARS-CoV-2 infection and no medical history that might, in the  
112 opinion of the attending clinician, put the patient at significant risk if they were to  
113 participate in the trial. Initially, recruitment was limited to patients aged at least 18 years  
114 but from 9 May 2020, the age limit was removed. Patients with known prolonged QTc  
115 interval or hypersensitivity to a macrolide antibiotic and those already receiving  
116 chloroquine or hydroxychloroquine were excluded from being randomised between  
117 azithromycin and usual care. Written informed consent was obtained from all patients,  
118 or a legal representative if they were too unwell or unable to provide consent.

### 119 **Randomisation and masking**

120 Baseline data were collected using a web-based case report form that included  
121 demographics, level of respiratory support, major comorbidities, suitability of the study  
122 treatment for a particular patient, and treatment availability at the study site (appendix  
123 pp 26-28). Eligible and consenting patients were assigned to either usual standard of  
124 care or usual standard of care plus azithromycin or one of the other available  
125 RECOVERY treatment arms using web-based simple (unstratified) randomisation with  
126 allocation concealed until after randomisation (appendix pp 23-25). Randomisation to

## Azithromycin for COVID-19

usual care was twice that of any of the active arms the patient was eligible for (e.g. 2:1 in favour of usual care if the patient was eligible for only one active arm, 2:1:1 if the patient was eligible for two active arms). For some patients, azithromycin was unavailable at the hospital at the time of enrolment or if a macrolide antibiotic was considered by the managing physician to be either definitely indicated or definitely contraindicated. These patients were excluded from the randomised comparison between azithromycin and usual care. Patients allocated to azithromycin were to receive azithromycin 500 mg by mouth, nasogastric tube, or intravenous injection once daily for 10 days or until discharge, if sooner. Allocated treatment was prescribed by the managing doctor. Participants and local study staff were not masked to the allocated treatment. The Steering Committee, investigators, and all others involved in the trial were masked to the outcome data during the trial.

### **Procedures**

A single online follow-up form was completed when participants were discharged, had died or at 28 days after randomisation, whichever occurred earliest (appendix p 29-35). Information was recorded on adherence to allocated study treatment, receipt of other COVID-19 treatments, duration of admission, receipt of respiratory or renal support, and vital status (including cause of death). In addition, routine healthcare and registry data were obtained including information on vital status (with date and cause of death), discharge from hospital, receipt of respiratory support, or renal replacement therapy.

### **Outcomes**

## Azithromycin for COVID-19

Outcomes were assessed at 28 days after randomisation, with further analyses specified at 6 months. The primary outcome was all-cause mortality. Secondary outcomes were time to discharge from hospital, and, among patients not on invasive mechanical ventilation at randomisation, invasive mechanical ventilation (including extra-corporeal membrane oxygenation) or death. Prespecified subsidiary clinical outcomes were cause-specific mortality, use of haemodialysis or haemofiltration, major cardiac arrhythmia (recorded in a subset), and receipt and duration of ventilation. Among those on invasive mechanical ventilation at randomisation, a subsidiary clinical outcome of successful cessation of invasive mechanical ventilation was defined as cessation within (and survival to) 28 days. Information on suspected serious adverse reactions was collected in an expedited fashion to comply with regulatory requirements.

### Statistical Analysis

An intention-to-treat comparison was conducted between patients randomised to azithromycin and patients randomised to usual care but for whom azithromycin was both available and suitable as a treatment. For the primary outcome of 28-day mortality, the log-rank observed minus expected statistic and its variance were used to both test the null hypothesis of equal survival curves (i.e., the log-rank test) and to calculate the one-step estimate of the average mortality rate ratio. We constructed Kaplan-Meier survival curves to display cumulative mortality over the 28-day period. The 2059 patients (27%) who had not been followed for 28 days and were not known to have died by the time of the data cut for this preliminary analysis (30 November 2020) were either censored on 30 November 2020 or, if they had already been discharged alive, were right-censored for mortality at day 29 (that is, in the absence of any information to the



## Azithromycin for COVID-19

contrary they were assumed to have survived 28 days). [Note: This censoring rule will not be necessary for the final report.] We used similar methods to analyse time to hospital discharge and successful cessation of invasive mechanical ventilation, with patients who died in hospital right-censored on day 29. Median time to discharge was derived from Kaplan-Meier estimates. For the pre-specified composite secondary outcome of invasive mechanical ventilation or death within 28 days (among those not receiving invasive mechanical ventilation at randomisation) and the subsidiary clinical outcomes of receipt of ventilation and use of haemodialysis or haemofiltration, the precise dates were not available and so the risk ratio was estimated instead.

Prespecified analyses of the primary outcome were performed separately in seven subgroups defined by characteristics at randomisation: age, sex, ethnicity, level of respiratory support, days since symptom onset, use of corticosteroids, and predicted 28-day mortality risk (appendix p 26). Observed effects within subgroup categories were compared using a chi-squared test for heterogeneity or trend, in accordance with the prespecified analysis plan.

Estimates of rate and risk ratios are shown with 95% confidence intervals. All p-values are 2-sided and are shown without adjustment for multiple testing. The full database is held by the study team which collected the data from study sites and performed the analyses at the Nuffield Department of Population Health, University of Oxford (Oxford, UK).

As stated in the protocol, appropriate sample sizes could not be estimated when the trial was being planned at the start of the COVID-19 pandemic (appendix p 26). As the trial

## Azithromycin for COVID-19

progressed, the trial steering committee, whose members were unaware of the results of the trial comparisons, determined that sufficient patients should be enrolled to provide at least 90% power at a two-sided p-value of 0.01 to detect a clinically relevant proportional reduction in the primary outcome of 20% between the two groups. Consequently, on 27 November 2020, the steering committee, blinded to the results, closed recruitment to the azithromycin comparison as sufficient patients had been enrolled.

Analyses were performed using SAS version 9.4 and R version 3.4.0. The trial is registered with ISRCTN (50189673) and clinicaltrials.gov (NCT04381936).

### **Role of the funding source**

The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

## **RESULTS**

Between 7 April 2020 and 27 November 2020, 9434 (57%) of 16443 patients enrolled into the RECOVERY trial were eligible to be randomly allocated to azithromycin (that is azithromycin was available in the hospital at the time and the attending clinician was of the opinion that the patient had no known indication for or contraindication to azithromycin, figure 1; appendix p 38). 2582 patients were randomly allocated to

## Azithromycin for COVID-19

214 azithromycin and 5182 were randomly allocated to usual care, with the remainder being  
215 randomly allocated to one of the other treatment arms. The mean age of study  
216 participants in this comparison was 65.3 years (SD 15.7) and the median time since  
217 symptom onset was 8 days (IQR 5 to 11 days) (table 1; appendix p 38).

218 Among the 5910 (76%) patients for whom a follow-up form has been completed to date,  
219 1760 (89%) allocated to azithromycin vs. 55 (1%) allocated to usual care received at  
220 least one dose, and 1836 (92%) vs. 606 (15%) received any macrolide antibiotic (figure  
221 1; appendix p 39). The median duration of treatment with azithromycin was 6 days (IQR  
222 3-9 days). Use of other treatments for COVID-19 was similar among patients allocated  
223 azithromycin and among those allocated usual care, with nearly one half receiving a  
224 corticosteroid, about one-fifth receiving remdesivir, and one-fifth receiving convalescent  
225 plasma.

226 We observed no significant difference in the proportion of patients who met the primary  
227 outcome of 28-day mortality between the two randomised groups (496 [19%] patients in  
228 the azithromycin group vs. 997 (19%) patients in the usual care group; rate ratio 1.00;  
229 95% confidence interval [CI], 0.90 to 1.12;  $p=0.99$ ; figure 2). We observed similar  
230 results across all pre-specified subgroups (figure 3). In an exploratory analysis restricted  
231 to the 6916 (89%) patients with a positive SARS-CoV-2 test result, the result was similar  
232 (rate ratio 0.99, 95% CI 0.88 to 1.10;  $p=0.81$ ).

233 Allocation to azithromycin was associated with a similar time until discharge from  
234 hospital alive as usual care (median 12 days vs. 13 days) and a similar probability of  
235 discharge alive within 28 days (60% vs. 59%, rate ratio 1.03, 95% CI 0.97 to 1.10,

## Azithromycin for COVID-19

p=0.29) (Table 2). Among those not on invasive mechanical ventilation at baseline, the number of patients progressing to the pre-specified composite secondary outcome of invasive mechanical ventilation or death among those allocated to azithromycin was similar to that among those allocated to usual care (21% vs. 22%, risk ratio 0.97, 95% CI 0.89 to 1.07, p=0.54). Allowing for multiple testing in interpretation of the results, there was no evidence that the effect of allocation to azithromycin vs. usual care on time until discharge from hospital alive or on invasive mechanical ventilation or death differed between pre-specified subgroups of patients (appendix p 43-44).

We found no significant differences in the prespecified subsidiary clinical outcomes of cause-specific mortality (appendix p 40), use of ventilation, successful cessation of invasive mechanical ventilation, or need for renal dialysis or haemofiltration (Table 2). We observed no significant differences in the frequency of new cardiac arrhythmias (appendix p 41). There was one report of a serious adverse reaction believed related to azithromycin: a case of pseudomembranous colitis from which the patient recovered with standard treatment.

## DISCUSSION

The results of this large randomised trial show that azithromycin is not an effective treatment for patients hospitalised with COVID-19. Allocation to azithromycin was not associated with reductions in mortality, duration of hospitalisation or the risk of being ventilated or dying for those not on ventilation at baseline. These results were consistent across the prespecified subgroups of age, sex, ethnicity, duration of

## Azithromycin for COVID-19

symptoms prior to randomisation, level of respiratory support at randomisation, use of corticosteroids, and baseline predicted risk of death at randomisation.

Azithromycin was proposed as a treatment for COVID-19 based on its immunomodulatory activity.<sup>7</sup> Although no major organization or professional society has recommended the routine use of azithromycin in COVID-19 unless there is evidence of bacterial super-infection, it has nevertheless been used widely in COVID-19 patients, particularly in combination with hydroxychloroquine.<sup>20-22</sup> Macrolides have long been suggested as potential therapies for inflammatory viral pneumonias but this has been based on in vitro, animal and observational data, with very little clinical trial evidence of benefit.<sup>11-13</sup> The benefit of dexamethasone in COVID-19 patients requiring respiratory support suggests that inflammation has a causal role in mortality.<sup>3</sup> Noting that the results were consistent regardless of whether patients were also being treated with a corticosteroid or not, we conclude that the immunomodulatory properties of azithromycin are either insufficient or off-target in COVID-19.

Macrolides are commonly used to treat bacterial infections of the lower respiratory tract because of their good activity against Gram positive bacteria and atypical pathogens such as *Mycoplasma pneumoniae* and *Legionella* species, and their excellent tissue penetration. More than 75% of hospitalised COVID-19 patients are prescribed antibiotics and the widespread clinical use of macrolides in COVID-19 is likely to be driven largely by concerns of bacterial superinfection rather than purported immunomodulatory activity.<sup>23</sup> It is therefore important to highlight that in patients with moderate or severe COVID-19, who might be expected to experience some burden of

## Azithromycin for COVID-19

280 secondary bacterial lung infection, there was no observed clinical benefit of  
 281 azithromycin use. This lack of effect may either reflect the relatively low rate of  
 282 secondary bacterial infection in COVID-19 or the widespread use of other antibiotics  
 283 such as  $\beta$ -lactam antibiotics, which may have abrogated any anti-bacterial benefit of  
 284 allocation to azithromycin in this trial.<sup>24,25</sup> Our results show that azithromycin confers no  
 285 clinical benefit in hospitalised COVID-19 patients, whether that be anti-inflammatory or  
 286 antimicrobial. Although we detected no harm to individual patients treated with  
 287 azithromycin, there is a risk of harm at a societal level from widespread use of  
 288 antimicrobial agents. Azithromycin is classified within the WHO Watch Group of  
 289 Antibiotics: antibiotics that have higher resistance potential and should be prioritized as  
 290 key targets of antimicrobial stewardship programs. In light of the new evidence from the  
 291 RECOVERY trial, the widespread use in COVID-19 patients of macrolides in particular  
 292 and antibiotics in general must be questioned.<sup>26</sup>

293 Our trial has some limitations: Detailed information on laboratory markers of  
 294 inflammatory status, co-existent bacterial infection, or use of non-macrolide antibiotics  
 295 was not collected, nor was information on radiological or physiological outcomes. This  
 296 initial report is based on complete follow-up for the primary outcome in 73% of patients  
 297 (and partial follow-up for the remaining 27%). However, collection of outcome  
 298 information both through case report forms and linkage to routine NHS records is  
 299 ongoing and, based on previous reports from this trial, will deliver complete follow-up  
 300 information for over 99% of patients by early January 2021. However, additional follow-  
 301 up is unlikely to change the conclusion that azithromycin has no meaningful benefit for  
 302 hospitalised patients with COVID-19.

## Azithromycin for COVID-19

Three other randomised controlled trials have assessed the efficacy of azithromycin for the treatment of COVID-19 in hospitalised patients, all of which additionally treated patients with hydroxychloroquine.<sup>15-17</sup> The COALITION I and COALITION II trials found that allocation of hospitalized patients with COVID-19 to azithromycin and hydroxychloroquine, was not associated with any improvement in mortality, duration of hospital stay, or clinical status as assessed using an ordinal outcome scale.<sup>15,16</sup> A small trial in Iran that randomised patients to hydroxychloroquine and lopinavir-ritonavir with or without azithromycin also found no significant difference in mortality or intensive care unit admission, but suggested a reduction in duration of hospital stay.<sup>17</sup> The total number of patients in all three prior trials combined was 1223, with 130 deaths. The RECOVERY trial, with 7764 participants and 1483 deaths in this assessment of azithromycin, is far better powered to detect modest treatment benefits; none were observed.

At the time of writing, 24 trials evaluating the use of macrolides in COVID-19 patients were registered in the WHO International Clinical Trials Registry Platform, of which two (COALITION I and COALITION II, described above) have published results. Of the remaining 22, 16 are studying macrolides in inpatients either alone or in combination with other putative treatments, whilst 6 are studying non-hospitalised patients with suspected or confirmed COVID-19.

Whilst our findings do not address the use of macrolides for the treatment of non-hospitalised COVID-19 patients with early, mild disease, the results do show that azithromycin is not an effective treatment for hospitalised COVID-19 patients.

## Azithromycin for COVID-19

325

### 326 **Contributors**

327 This manuscript was initially drafted by PWH and MJL, further developed by the Writing  
328 Committee, and approved by all members of the trial steering committee. PWH and MJL  
329 vouch for the data and analyses, and for the fidelity of this report to the study protocol  
330 and data analysis plan. PWH, MM, JKB, LCC, SNF, TJ, KJ, WSL, AM, KR, EJ, RH, and  
331 MJL designed the trial and study protocol. MM, AR, G P-A, CB, BP, DC, AU, AA, ST,  
332 BY, RB, SS, DM, RH, the Data Linkage team at the RECOVERY Coordinating Centre,  
333 and the Health Records and Local Clinical Centre staff listed in the appendix collected  
334 the data. ES, NS, and JRE did the statistical analysis. All authors contributed to data  
335 interpretation and critical review and revision of the manuscript. PWH and JL had  
336 access to the study data and had final responsibility for the decision to submit for  
337 publication.

338



## Azithromycin for COVID-19

### 339 Writing Committee (on behalf of the RECOVERY Collaborative Group):

340 Professor Peter W Horby PhD FRCP,<sup>a,\*</sup> Alistair Roddick MBBS,<sup>b,c,\*</sup> Enti Spata,<sup>b,d,\*</sup>  
 341 Natalie Staplin PhD,<sup>b,d</sup> Professor Jonathan R Emberson PhD,<sup>b,d</sup> Guilherme Pessoa-  
 342 Amorim MD,<sup>b,e</sup> Leon Peto PhD,<sup>a,c</sup> Mark Campbell FRCPATH,<sup>b,c</sup> Professor Christopher  
 343 Brightling FRCP,<sup>f</sup> Benjamin Prudon FRCP,<sup>f</sup> David Chadwick PhD,<sup>h</sup> Andrew Ustianowski  
 344 PhD,<sup>i</sup> Abdul Ashish MD,<sup>j</sup> Stacy Todd PhD,<sup>k</sup> Bryan Yates MRCP,<sup>l</sup> Robert Buttery PhD,<sup>m</sup>  
 345 Stephen Scott PhD,<sup>n</sup> Diego Maseda MD,<sup>o</sup> J Kenneth Baillie MD PhD,<sup>p</sup> Professor Maya  
 346 H Buch PhD FRCP,<sup>q</sup> Professor Lucy C Chappell PhD,<sup>r</sup> Professor Jeremy Day PhD  
 347 FRCP,<sup>a,s</sup> Professor Saul N Faust PhD FRCPCH,<sup>t</sup> Professor Thomas Jaki PhD,<sup>u,v</sup> Katie  
 348 Jeffery PhD FRCP FRCPATH,<sup>c</sup> Professor Edmund Juszczak MSc,<sup>w</sup> Professor Wei Shen  
 349 Lim FRCP,<sup>w,x</sup> Professor Alan Montgomery PhD,<sup>w</sup> Professor Andrew Mumford PhD,<sup>y</sup>  
 350 Kathryn Rowan PhD,<sup>z</sup> Professor Guy Thwaites PhD FRCP,<sup>a,s</sup> Marion Mafham MD,<sup>b,t</sup>  
 351 Professor Richard Haynes DM,<sup>b,d,t</sup> Professor Martin J Landray PhD FRCP.<sup>b,d,e,t</sup>

352

353 <sup>a</sup> Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

354 <sup>b</sup> Nuffield Department of Population Health, University of Oxford, Oxford, United  
 355 Kingdom

356 <sup>c</sup> Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

357 <sup>d</sup> MRC Population Health Research Unit, University of Oxford, Oxford, United Kingdom

## Azithromycin for COVID-19

- 358 <sup>e</sup> NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS  
359 Foundation Trust, Oxford, United Kingdom
- 360 <sup>f</sup> Institute for Lung Health, Leicester NIHR Biomedical Research Centre, University of  
361 Leicester, Leicester, United Kingdom
- 362 <sup>g</sup> Department of Respiratory Medicine, North Tees & Hartlepool NHS Foundation Trust,  
363 Stockton-on-Tees, United Kingdom
- 364 <sup>h</sup> Centre for Clinical Infection, James Cook University Hospital, Middlesbrough, United  
365 Kingdom
- 366 <sup>i</sup> North Manchester General Hospital, Pennine Acute Hospitals NHS Trust, Bury, United  
367 Kingdom
- 368 <sup>j</sup> Wrightington Wigan and Leigh NHS Foundation Trust, Wigan, United Kingdom
- 369 <sup>k</sup> Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom
- 370 <sup>l</sup> Northumbria Healthcare NHS Foundation Trust, North Tyneside, United Kingdom
- 371 <sup>m</sup> North West Anglia NHS Foundation Trust, Peterborough, United Kingdom
- 372 <sup>n</sup> The Countess of Chester Hospital NHS Foundation Trust, Chester, United Kingdom
- 373 <sup>o</sup> Mid Cheshire Hospitals NHS Foundation Trust, Crewe, United Kingdom
- 374 <sup>p</sup> Roslin Institute, University of Edinburgh, Edinburgh, United Kingdom

## Azithromycin for COVID-19

375 <sup>q</sup> Centre for Musculoskeletal Research, University of Manchester, Manchester, and  
376 NIHR Manchester Biomedical Research Centre, United Kingdom.

377 <sup>r</sup> School of Life Course Sciences, King's College London, London, United Kingdom

378 <sup>s</sup> Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam

379 <sup>t</sup> NIHR Southampton Clinical Research Facility and Biomedical Research Centre,  
380 University Hospital Southampton NHS Foundation Trust and University of Southampton,  
381 Southampton, United Kingdom

382 <sup>u</sup> Department of Mathematics and Statistics, Lancaster University, Lancaster, United  
383 Kingdom

384 <sup>v</sup> MRC Biostatistics Unit, University of Cambridge, Cambridge, United Kingdom

385 <sup>w</sup> School of Medicine, University of Nottingham, Nottingham, United Kingdom

386 <sup>x</sup> Respiratory Medicine Department, Nottingham University Hospitals NHS Trust,  
387 Nottingham, United Kingdom

388 <sup>y</sup> School of Cellular and Molecular Medicine, University of Bristol, Bristol, United  
389 kingdom

390 <sup>z</sup> Intensive Care National Audit & Research Centre, London, United Kingdom

391 <sup>\*,†</sup> equal contribution

392

393

## Azithromycin for COVID-19

### 394 **Data Monitoring Committee**

395 Peter Sandercock, Janet Darbyshire, David DeMets, Robert Fowler, David Laloo, Ian  
396 Roberts, Janet Wittes.

### 397 **Declaration of interests**

398 The authors have no conflict of interest or financial relationships relevant to the  
399 submitted work to disclose. No form of payment was given to anyone to produce the  
400 manuscript. All authors have completed and submitted the ICMJE Form for Disclosure  
401 of Potential Conflicts of Interest. The Nuffield Department of Population Health at the  
402 University of Oxford has a staff policy of not accepting honoraria or consultancy fees  
403 directly or indirectly from industry (see [https://www.ndph.ox.ac.uk/files/about/ndph-](https://www.ndph.ox.ac.uk/files/about/ndph-independence-of-research-policy-jun-20.pdf)  
404 [independence-of-research-policy-jun-20.pdf](https://www.ndph.ox.ac.uk/files/about/ndph-independence-of-research-policy-jun-20.pdf)).

### 405 **Data sharing**

406 The protocol, consent form, statistical analysis plan, definition & derivation of clinical  
407 characteristics & outcomes, training materials, regulatory documents, and other relevant  
408 study materials are available online at [www.recoverytrial.net](http://www.recoverytrial.net). As described in the  
409 protocol, the trial Steering Committee will facilitate the use of the study data and  
410 approval will not be unreasonably withheld. Deidentified participant data will be made  
411 available to bona fide researchers registered with an appropriate institution within 3  
412 months of publication. However, the Steering Committee will need to be satisfied that  
413 any proposed publication is of high quality, honours the commitments made to the study  
414 participants in the consent documentation and ethical approvals, and is compliant with

## Azithromycin for COVID-19

relevant legal and regulatory requirements (e.g. relating to data protection and privacy). The Steering Committee will have the right to review and comment on any draft manuscripts prior to publication. Data will be made available in line with the policy and procedures described at: <https://www.ndph.ox.ac.uk/data-access>. Those wishing to request access should complete the form at [https://www.ndph.ox.ac.uk/files/about/data\\_access\\_enquiry\\_form\\_13\\_6\\_2019.docx](https://www.ndph.ox.ac.uk/files/about/data_access_enquiry_form_13_6_2019.docx) and e-mailed to: [data.access@ndph.ox.ac.uk](mailto:data.access@ndph.ox.ac.uk)

## Acknowledgements

Above all, we would like to thank the thousands of patients who participated in this study. We would also like to thank the many doctors, nurses, pharmacists, other allied health professionals, and research administrators at 176 NHS hospital organisations across the whole of the UK, supported by staff at the National Institute of Health Research (NIHR) Clinical Research Network, NHS DigiTrials, Public Health England, Department of Health & Social Care, the Intensive Care National Audit & Research Centre, Public Health Scotland, National Records Service of Scotland, the Secure Anonymised Information Linkage (SAIL) at University of Swansea, and the NHS in England, Scotland, Wales and Northern Ireland.

The RECOVERY trial is supported by a grant to the University of Oxford from UK Research and Innovation/NIHR (Grant reference: MC\_PC\_19056) and by core funding provided by NIHR Oxford Biomedical Research Centre, Wellcome, the Bill and Melinda Gates Foundation, the Department for International Development, Health Data Research

## Azithromycin for COVID-19

UK, the Medical Research Council Population Health Research Unit, the NIHR Health Protection Unit in Emerging and Zoonotic Infections, and NIHR Clinical Trials Unit Support Funding. TJ is supported by a grant from UK Medical Research Council (MC\_UU\_0002/14) and an NIHR Senior Research Fellowship (NIHR-SRF-2015-08-001). WSL is supported by core funding provided by NIHR Nottingham Biomedical Research Centre. Abbvie contributed some supplies of lopinavir-ritonavir for use in this study. Tocilizumab was provided free of charge for this study by Roche Products Limited. REGN-COV2 was provided free of charge for this study by Regeneron.

The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care.

### **Conflicts of interest**

The authors have no conflict of interest or financial relationships relevant to the submitted work to disclose. No form of payment was given to anyone to produce the manuscript. All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. The Nuffield Department of Population Health at the University of Oxford has a staff policy of not accepting honoraria or consultancy fees directly or indirectly from industry (see <https://www.ndph.ox.ac.uk/files/about/ndph-independence-of-research-policy-jun-20.pdf>).

## Azithromycin for COVID-19

### References

1. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. *Bmj* 2020; **369**: m1985.
2. Carsana L, Sonzogni A, Nasr A, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. *Lancet Infect Dis* 2020.
3. Horby P, Lim WS, Emberson JR, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. *N Engl J Med* 2020.
4. Sterne JAC, Diaz J, Villar J, et al. Corticosteroid therapy for critically ill patients with COVID-19: A structured summary of a study protocol for a prospective meta-analysis of randomized trials. *Trials* 2020; **21**(1): 734.
5. Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. *Clin Microbiol Rev* 2010; **23**(3): 590-615.
6. Shinkai M, Henke MO, Rubin BK. Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action. *Pharmacol Ther* 2008; **117**(3): 393-405.
7. Zimmermann P, Ziesenitz VC, Curtis N, Ritz N. The Immunomodulatory Effects of Macrolides-A Systematic Review of the Underlying Mechanisms. *Front Immunol* 2018; **9**: 302.
8. Spagnolo P, Fabbri LM, Bush A. Long-term macrolide treatment for chronic respiratory disease. *Eur Respir J* 2013; **42**(1): 239-51.
9. Smith D, Du Rand IA, Addy C, et al. British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease. *BMJ Open Respir Res* 2020; **7**(1).
10. Touret F, Gilles M, Barral K, et al. In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication. *Sci Rep* 2020; **10**(1): 13093.
11. Oliver ME, Hinks TSC. Azithromycin in viral infections. *Rev Med Virol* 2020: e2163.
12. Hui DS, Lee N, Chan PK, Beigel JH. The role of adjuvant immunomodulatory agents for treatment of severe influenza. *Antiviral Res* 2018; **150**: 202-16.
13. Lee N, Wong CK, Chan MCW, et al. Anti-inflammatory effects of adjunctive macrolide treatment in adults hospitalized with influenza: A randomized controlled trial. *Antiviral Res* 2017; **144**: 48-56.

## Azithromycin for COVID-19

- 491 14. Hung IFN, To KKW, Chan JFW, et al. Efficacy of Clarithromycin-Naproxen-  
492 Oseltamivir Combination in the Treatment of Patients Hospitalized for Influenza  
493 A(H3N2) Infection: An Open-label Randomized, Controlled, Phase IIb/III Trial. *Chest*  
494 2017; **151**(5): 1069-80.
- 495 15. Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without  
496 Azithromycin in Mild-to-Moderate Covid-19. *New England Journal of Medicine* 2020.
- 497 16. Furtado RHM, Berwanger O, Fonseca HA, et al. Azithromycin in addition to  
498 standard of care versus standard of care alone in the treatment of patients admitted to  
499 the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial.  
500 *Lancet* 2020; **396**(10256): 959-67.
- 501 17. Sekhavati E, Jafari F, SeyedAlinaghi S, et al. Safety and effectiveness of  
502 azithromycin in patients with COVID-19: An open-label randomised trial. *Int J Antimicrob*  
503 *Agents* 2020; **56**(4): 106143.
- 504 18. Horby P, Mafham M, Linsell L, et al. Effect of Hydroxychloroquine in Hospitalized  
505 Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled  
506 trial. *medRxiv* 2020: 2020.07.15.20151852.
- 507 19. Recovery Collaborative Group, Horby PW, Mafham M, et al. Lopinavir-ritonavir in  
508 patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled,  
509 open-label, platform trial. *Lancet* 2020.
- 510 20. Sultana J, Cutroneo PM, Crisafulli S, Puglisi G, Caramori G, Trifiro G.  
511 Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence  
512 and Prescribing Guidelines. *Drug Saf* 2020; **43**(8): 691-8.
- 513 21. SERMO. Sermo reports jury is still out on Remdesivir. 2020.  
514 [https://www.sermo.com/press-releases/sermo-reports-jury-is-still-out-on-remdesivir-31-](https://www.sermo.com/press-releases/sermo-reports-jury-is-still-out-on-remdesivir-31-of-physicians-who-have-used-remdesivir-rate-it-as-highly-effective-31-rate-it-with-low-effectiveness-38-rate-it-as-somewhere-in-the-middle/)  
515 [of-physicians-who-have-used-remdesivir-rate-it-as-highly-effective-31-rate-it-with-low-](https://www.sermo.com/press-releases/sermo-reports-jury-is-still-out-on-remdesivir-31-of-physicians-who-have-used-remdesivir-rate-it-as-highly-effective-31-rate-it-with-low-effectiveness-38-rate-it-as-somewhere-in-the-middle/)  
516 [effectiveness-38-rate-it-as-somewhere-in-the-middle/](https://www.sermo.com/press-releases/sermo-reports-jury-is-still-out-on-remdesivir-31-of-physicians-who-have-used-remdesivir-rate-it-as-highly-effective-31-rate-it-with-low-effectiveness-38-rate-it-as-somewhere-in-the-middle/).
- 517 22. Geleris J, Sun Y, Platt J, et al. Observational Study of Hydroxychloroquine in  
518 Hospitalized Patients with Covid-19. *N Engl J Med* 2020.
- 519 23. Hall M, Pritchard M, Dankwa EA, et al. ISARIC Clinical Data Report 20  
520 November 2020. *medRxiv* 2020: 2020.07.17.20155218.
- 521 24. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19:  
522 a systematic review and meta-analysis. *J Infect* 2020; **81**(2): 266-75.
- 523 25. Rawson TM, Moore LSP, Zhu N, et al. Bacterial and Fungal Coinfection in  
524 Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial  
525 Prescribing. *Clin Infect Dis* 2020; **71**(9): 2459-68.



It is made available under a [CC-BY 4.0 International license](#).

## Azithromycin for COVID-19

- 526 26. Ginsburg AS, Klugman KP. COVID-19 pneumonia and the appropriate use of  
527 antibiotics. *Lancet Glob Health* 2020; **8**(12): e1453-e4.  
528

529

## Azithromycin for COVID-19

582 **Table 1: Baseline characteristics**

	Treatment allocation	
	Azithromycin (n=2582)	Usual care (n=5182)
Age, years	65.4 (15.6)	65.2 (15.7)
<70*	1508 (58%)	3015 (58%)
≥70 to <80	615 (24%)	1167 (23%)
≥80	459 (18%)	1000 (19%)
Sex		
Male	1603 (62%)	3216 (62%)
Female†	979 (38%)	1966 (38%)
Ethnicity		
White	1867 (72%)	3773 (73%)
Black, Asian, and minority ethnic	363 (14%)	708 (14%)
Unknown	352 (14%)	701 (14%)
Number of days since symptom onset	8 (5-11)	8 (5-11)
Number of days since admission to hospital	2 (1-4)	2 (1-4)
Respiratory support received		
No oxygen received	490 (19%)	918 (18%)
Oxygen only ‡	1940 (75%)	3964 (76%)
Invasive mechanical ventilation	152 (6%)	300 (6%)
Previous diseases		
Diabetes	700 (27%)	1433 (28%)
Heart disease	693 (27%)	1350 (26%)
Chronic lung disease	621 (24%)	1314 (25%)
Tuberculosis	3 (<1%)	16 (<1%)
HIV	7 (<1%)	22 (<1%)
Severe liver disease §	45 (2%)	65 (1%)
Severe kidney impairment ¶	155 (6%)	334 (6%)
Any of the above	1507 (58%)	3014 (58%)
Use of corticosteroids		
Yes	1567 (61%)	3172 (61%)
No	183 (7%)	399 (8%)
Unknown <sup>^</sup>	832 (32%)	1611 (31%)
Severe acute respiratory syndrome coronavirus 2 test result		
Positive	2282 (88%)	4634 (89%)
Negative	195 (8%)	371 (7%)
Unknown	105 (4%)	177 (3%)

Data are mean (SD), n (%), or median (IQR). \* Includes 26 children (<18 years).

† Includes 25 pregnant women. ‡ Includes non-invasive ventilation. § Defined as requiring ongoing specialist care. ¶ Defined as estimated glomerular filtration rate <30 mL/min per 1.73 m<sup>2</sup>. <sup>^</sup> Information on use of corticosteroids was collected from 18 June 2020 onwards following announcement of the results of the dexamethasone comparison from the RECOVERY trial.

## Azithromycin for COVID-19

**Table 2: Effect of allocation to azithromycin on key study outcomes**

	Treatment allocation		RR (95% CI)	p-value
	Azithromycin (n=2582)	Usual care (n=5182)		
Primary outcome:				
28-day mortality	496 (19%)	997 (19%)	1.00 (0.90-1.12)	0.99
Secondary outcomes:				
Median time to being discharged alive, days	12	13		
Discharged from hospital within 28 days	1554 (60%)	3066 (59%)	1.03 (0.97-1.10)	0.29
Receipt of invasive mechanical ventilation or death*	517/2430 (21%)	1069/4882 (22%)	0.97 (0.89-1.07)	0.54
Invasive mechanical ventilation	154/2430 (6%)	325/4882 (7%)	0.95 (0.79-1.15)	0.60
Death	442/2430 (18%)	891/4882 (18%)	1.00 (0.90-1.10)	0.95
Subsidiary clinical outcomes				
Receipt of ventilation †	27/490 (6%)	50/918 (5%)	1.01 (0.64-1.59)	0.96
Non-invasive ventilation	24/490 (5%)	43/918 (5%)	1.05 (0.64-1.70)	0.86
Invasive mechanical ventilation	8/490 (2%)	11/918 (1%)	1.36 (0.55-3.37)	0.50
Successful cessation of invasive mechanical ventilation ‡	42/152 (28%)	95/300 (32%)	0.84 (0.59-1.20)	0.33
Use of haemodialysis or haemofiltration §	79/2548 (3%)	158/5125 (3%)	1.01 (0.77-1.31)	0.97

Data are n (%) or n/N (%), unless otherwise indicated. RR=rate ratio for the outcomes of 28-day mortality, hospital discharge and successful cessation of invasive mechanical ventilation, and risk ratio for other outcomes. \* Analyses exclude those on invasive mechanical ventilation at randomisation. † Analyses exclude those on any form of ventilation at randomisation. ‡ Analyses restricted to those on invasive mechanical ventilation at randomisation. § Analyses exclude those on haemodialysis or haemofiltration at randomisation.

## Azithromycin for COVID-19

### Figures

#### Figure 1: Trial profile

ITT=intention to treat. # Number recruited overall during period that adult participants could be recruited into azithromycin comparison. \* 1986/2582 (77%) and 3924/5182 (76%) patients have a completed follow-up form at time of analysis. 3994 patients were additionally randomised to convalescent plasma vs REGN-COV2 vs usual care (1320 [51%] patients allocated to azithromycin vs 2674 [52%] patients allocated usual care) and 975 patients were additionally randomised to aspirin vs usual care (323 [13%] patients allocated to azithromycin vs 652 [13%] patients allocated usual care. † Includes 197/2582 (7.6%) patients in the azithromycin arm and 446/5182 (8.6%) patients in the usual care arm allocated to tocilizumab.


#### Figure 2: Effect of allocation to azithromycin on 28-day mortality

#### Figure 3: Effect of allocation to azithromycin on 28-day mortality by baseline characteristics

Subgroup-specific rate ratio estimates are represented by squares (with areas of the squares proportional to the amount of statistical information) and the lines through them correspond to the 95% CIs. The ethnicity and days since onset subgroups exclude those with missing data, but these patients are included in the overall summary diamond. \* Includes patients receiving non-invasive ventilation. Information on use of corticosteroids was collected from 18 June 2020 onwards following announcement of the results of the dexamethasone comparison from the RECOVERY trial.


## Figure 1: Trial profile

medRxiv preprint doi: <https://doi.org/10.1101/2020.12.10.20245944>; this version posted December 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.



**Figure 2: Effect of allocation to azithromycin on 28-day mortality**  
medRxiv preprint doi: <https://doi.org/10.1101/2020.12.10.20245944>; this version posted December 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY 4.0 International license](#).



**Figure 3: Effect of allocation to azithromycin on 28-day mortality by baseline characteristics**

